Insurance coverage for Botox and CGRP monoclonal antibody

It has come to the attention of the members of the Canadian Headache Society that some insurance companies are refusing to cover the combination of Botox and a CGRP monoclonal antibody (BTX + CGRP MAB). Currently available CGRP monoclonal antibodies are erenumab (Aimovig) and
galcanezumab (Emgality), Fremanezumab (Ajovy) and eptinezumab (Viyepti). All CGRP antibodies have shown effectiveness and safety in robust randomized-controlled trials (1).